Original paper
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Abstract
Importance
A randomized clinical trial is needed to determine whether the second-generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).Objective
To determine whether dasatinib given at a daily dosage of 80 mg/m2is more effective than imatinib mesylate at a daily...Paper Details
Title
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Published Date
Jan 16, 2020
Journal
Volume
6
Issue
3
Pages
358 - 358